BlackRock’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.6M Buy
2,411,793
+121,261
+5% +$1.87M ﹤0.01% 2901
2025
Q4
$46.6M Sell
2,290,532
-426,621
-16% -$7.48M ﹤0.01% 2562
2025
Q3
$43M Sell
2,717,153
-15,470
-0.6% -$229K ﹤0.01% 2600
2025
Q2
$36.5M Sell
2,732,623
-52,614
-2% -$710K ﹤0.01% 2633
2025
Q1
$28.4M Buy
2,785,237
+55,959
+2% +$650K ﹤0.01% 2732
2024
Q4
$43.2M Buy
2,729,278
+96,670
+4% +$5.02M ﹤0.01% 2546
2024
Q3
$153M Buy
2,632,608
+119,364
+5% +$5.9M ﹤0.01% 1816
2024
Q2
$115M Buy
2,513,244
+347,234
+16% +$18.7M ﹤0.01% 1945
2024
Q1
$143M Buy
2,166,010
+129,222
+6% +$7.66M ﹤0.01% 1850
2023
Q4
$81M Buy
2,036,788
+169,439
+9% +$5.31M ﹤0.01% 2206
2023
Q3
$59.5M Buy
1,867,349
+122,952
+7% +$4.59M ﹤0.01% 2305
2023
Q2
$70.1M Buy
1,744,397
+67,137
+4% +$2.94M ﹤0.01% 2282
2023
Q1
$71.6M Buy
1,677,260
+38,934
+2% +$1.97M ﹤0.01% 2223
2022
Q4
$78.7M Buy
1,638,326
+177,136
+12% +$8.27M ﹤0.01% 2173
2022
Q3
$55M Buy
1,461,190
+64,847
+5% +$2.25M ﹤0.01% 2370
2022
Q2
$38.6M Buy
1,396,343
+98,297
+8% +$4.31M ﹤0.01% 2664
2022
Q1
$70.6M Buy
1,298,046
+11,520
+0.9% +$591K ﹤0.01% 2361
2021
Q4
$75.3M Buy
1,286,526
+52,368
+4% +$2.61M ﹤0.01% 2390
2021
Q3
$48.8M Sell
1,234,158
-5,215
-0.4% -$186K ﹤0.01% 2673
2021
Q2
$52.6M Buy
1,239,373
+15,328
+1% +$830K ﹤0.01% 2667
2021
Q1
$75.3M Buy
1,224,045
+24,844
+2% +$1.57M ﹤0.01% 2358
2020
Q4
$84.6M Buy
1,199,201
+544,559
+83% +$34.3M ﹤0.01% 2171
2020
Q3
$25.2M Sell
654,642
-5,679
-0.9% -$225K ﹤0.01% 2731
2020
Q2
$24.8M Buy
+660,321
New +$20.3M ﹤0.01% 2685

Other funds holding KROS